FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983078204> ?p ?o ?g. }

• W1983078204 endingPage "1251" @default.
• W1983078204 startingPage "1239" @default.
• W1983078204 abstract "Autoimmune mechanisms have recently been implicated in the pathogenesis of an increasing number of neuromuscular diseases. Many of these diseases can be treated with immunotherapeutic agents that are currently available—often with striking success. However, lack of specificity and adverse side effects impose limits on the effectiveness of these immunosuppressive treatments. This article reviews the basic principles of autoimmunity and immune tolerance, and outlines strategies that produce (a) generalized immunosuppression; (b) “selective” immunotherapy; and (c) “antigen-specific” immunotherapy. General immunosuppressive treatments, which are the ones most commonly used in current practice, down-regulate the immune system at multiple levels in “shotgun” fashion. The agents described here include: adrenal corticosteroids, azathioprine, cyclophosphamide, chlorambucil, methotrexate, total lymphoid irradiation, plasmapheresis, and intravenous immunoglobulin. “Selective” immunotherapeutic strategies are designed to interfere with mechanisms intrinsic to the immune system. Agents that are now being used clinically, or are in advanced stages of development include: cyclosporin A, which interferes with synthesis of the cytokine interleukin 2 (IL2); IL2 toxin, which binds to IL2 receptors on activated T cells, is endocytosed, and kills the cells; and CTLA41g, which blocks costimulatory molecules, thus preventing full activation of T cells. We have found that combinations of the selective agents may enhance their effectiveness. “Specific” strategies are designed to inactivate or suppress antigen-specific T cells. Oral administration of autoantigens has been shown to prevent experimental autoimmune diseases specifically, but the conditions required to suppress ongoing autoimmune diseases are capricious and depend on many factors. Finally, we describe a method that is still in the experimental stage, which is designed to modify the individual's own antigen-presenting cells so that they will target and inactivate antigen-specific T cells, and thereby turn off the specific autoimmune response. Currently available immunosuppressive methods can now be used successfully to treat many autoimmune neuromuscular diseases, and the application of selective and specific immunotherapeutic strategies promises more precise and effective treatment in the future. © 1996 John Wiley & Sons, Inc." @default.
• W1983078204 created "2016-06-24" @default.
• W1983078204 creator A5019916188 @default.
• W1983078204 date "1996-10-01" @default.
• W1983078204 modified "2023-10-14" @default.
• W1983078204 title "Immunotherapy in neuromuscular disorders: Current and future strategies" @default.
• W1983078204 cites W1489559278 @default.
• W1983078204 cites W1490998575 @default.
• W1983078204 cites W1492874213 @default.
• W1983078204 cites W1500134182 @default.
• W1983078204 cites W1536173140 @default.
• W1983078204 cites W1600545823 @default.
• W1983078204 cites W1604301586 @default.
• W1983078204 cites W1917800718 @default.
• W1983078204 cites W1966959350 @default.
• W1983078204 cites W1968274103 @default.
• W1983078204 cites W1971315860 @default.
• W1983078204 cites W1974374706 @default.
• W1983078204 cites W1978790143 @default.
• W1983078204 cites W1979105454 @default.
• W1983078204 cites W1979841260 @default.
• W1983078204 cites W1981513836 @default.
• W1983078204 cites W1992790199 @default.
• W1983078204 cites W1997719965 @default.
• W1983078204 cites W2002003044 @default.
• W1983078204 cites W2012986854 @default.
• W1983078204 cites W2013289639 @default.
• W1983078204 cites W2017756260 @default.
• W1983078204 cites W2018252071 @default.
• W1983078204 cites W2019383691 @default.
• W1983078204 cites W2020317622 @default.
• W1983078204 cites W2034249407 @default.
• W1983078204 cites W2037626742 @default.
• W1983078204 cites W2041943167 @default.
• W1983078204 cites W2047616433 @default.
• W1983078204 cites W2049056633 @default.
• W1983078204 cites W2051645986 @default.
• W1983078204 cites W2052022784 @default.
• W1983078204 cites W2052168585 @default.
• W1983078204 cites W2054456664 @default.
• W1983078204 cites W2057780554 @default.
• W1983078204 cites W2058230154 @default.
• W1983078204 cites W2066680723 @default.
• W1983078204 cites W2069073496 @default.
• W1983078204 cites W2069700888 @default.
• W1983078204 cites W2075376701 @default.
• W1983078204 cites W2077228061 @default.
• W1983078204 cites W2080113479 @default.
• W1983078204 cites W2080956086 @default.
• W1983078204 cites W2087013294 @default.
• W1983078204 cites W2095252242 @default.
• W1983078204 cites W2095788709 @default.
• W1983078204 cites W2099893709 @default.
• W1983078204 cites W2103838865 @default.
• W1983078204 cites W2104889734 @default.
• W1983078204 cites W2115423672 @default.
• W1983078204 cites W2176716563 @default.
• W1983078204 cites W2244950998 @default.
• W1983078204 cites W2315610003 @default.
• W1983078204 cites W2331818774 @default.
• W1983078204 cites W4248406156 @default.
• W1983078204 doi "https://doi.org/10.1002/(sici)1097-4598(199610)19:10<1239::aid-mus1>3.0.co;2-f" @default.
• W1983078204 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8808649" @default.
• W1983078204 hasPublicationYear "1996" @default.
• W1983078204 type Work @default.
• W1983078204 sameAs 1983078204 @default.
• W1983078204 citedByCount "34" @default.
• W1983078204 countsByYear W19830782042013 @default.
• W1983078204 countsByYear W19830782042017 @default.
• W1983078204 crossrefType "journal-article" @default.
• W1983078204 hasAuthorship W1983078204A5019916188 @default.
• W1983078204 hasConcept C126322002 @default.
• W1983078204 hasConcept C203014093 @default.
• W1983078204 hasConcept C2776760755 @default.
• W1983078204 hasConcept C2777701055 @default.
• W1983078204 hasConcept C2778105408 @default.
• W1983078204 hasConcept C2779134260 @default.
• W1983078204 hasConcept C2780130043 @default.
• W1983078204 hasConcept C2780252810 @default.
• W1983078204 hasConcept C71924100 @default.
• W1983078204 hasConcept C8891405 @default.
• W1983078204 hasConceptScore W1983078204C126322002 @default.
• W1983078204 hasConceptScore W1983078204C203014093 @default.
• W1983078204 hasConceptScore W1983078204C2776760755 @default.
• W1983078204 hasConceptScore W1983078204C2777701055 @default.
• W1983078204 hasConceptScore W1983078204C2778105408 @default.
• W1983078204 hasConceptScore W1983078204C2779134260 @default.
• W1983078204 hasConceptScore W1983078204C2780130043 @default.
• W1983078204 hasConceptScore W1983078204C2780252810 @default.
• W1983078204 hasConceptScore W1983078204C71924100 @default.
• W1983078204 hasConceptScore W1983078204C8891405 @default.
• W1983078204 hasIssue "10" @default.
• W1983078204 hasLocation W19830782041 @default.
• W1983078204 hasLocation W19830782042 @default.
• W1983078204 hasOpenAccess W1983078204 @default.
• W1983078204 hasPrimaryLocation W19830782041 @default.
• W1983078204 hasRelatedWork W1966858596 @default.
• W1983078204 hasRelatedWork W1988960013 @default.

• next